Treatment decisions in MS: Shifting the goal posts?

The therapeutic landscape in MS continually evolving as more effective therapies emerge and become increasingly utilized. Highly effective therapies, now include therapies with more favourable safety profiles and improved safety mitigation strategies. 

Given the ability to better prevent MRI changes, relapses, and subsequent disability, the expectations are growing and the bar for deciding when to switch DMTs is lowering.

Increasing comfort with the use of newer and higher efficacy DMTs coupled with better evidence regarding the ideal threshold to switch will likely result in the use of more efficacious therapies being used earlier in the disease course.

Look into this timely editorial: